Aktienanalyse zu Natera Inc (NTRA)NTRANatera Inc

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Natera Inc is a good buy right now due to its recent FDA Breakthrough Device Designation for its cancer detection assay, which could significantly enhance its market position. Additionally, the stock has shown a remarkable year-to-date change of +75.10% and a one-year change of +130.07%, reflecting strong growth momentum. However, the company is currently facing a net loss of $192.3 million, which is a risk to consider.

6 analysts cover NTRA: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 262.92.